175 related articles for article (PubMed ID: 35398250)
1. Pivotal clinical trials with patient-reported outcome measures in premarket approval applications for high-risk medical devices from 2005 to 2018: Review, examples, and regulatory considerations.
Zhang B; Shankara SB; Guo J; Zhang H
Contemp Clin Trials; 2022 May; 116():106757. PubMed ID: 35398250
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
Rathi VK; Krumholz HM; Masoudi FA; Ross JS
JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
[TBL] [Abstract][Full Text] [Related]
3. Design and analysis of crossover trials for investigating high-risk medical devices: A review.
Zhang B; Guo J; Zhang H
Contemp Clin Trials Commun; 2022 Dec; 30():101004. PubMed ID: 36164356
[TBL] [Abstract][Full Text] [Related]
4. Risk of Recall Among Medical Devices Undergoing US Food and Drug Administration 510(k) Clearance and Premarket Approval, 2008-2017.
Dubin JR; Simon SD; Norrell K; Perera J; Gowen J; Cil A
JAMA Netw Open; 2021 May; 4(5):e217274. PubMed ID: 33956132
[TBL] [Abstract][Full Text] [Related]
5. Spinal devices in the United States-investigational device exemption trials and premarket approval of class III devices.
Golish SR; Reed ML
Spine J; 2017 Jan; 17(1):150-157. PubMed ID: 27737804
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and use of patient-reported outcomes of clinical trials for high-risk neurological medical devices that received FDA premarket approval from 2001 to 2022.
Ryan ME; Srivastava S; Wan L; Yang G; Zhang B
Contemp Clin Trials Commun; 2024 Feb; 37():101254. PubMed ID: 38269047
[TBL] [Abstract][Full Text] [Related]
7. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
Samuel AM; Rathi VK; Grauer JN; Ross JS
Clin Orthop Relat Res; 2016 Apr; 474(4):1053-68. PubMed ID: 26584802
[TBL] [Abstract][Full Text] [Related]
8. FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012.
Rome BN; Kramer DB; Kesselheim AS
JAMA; 2014 Jan 22-29; 311(4):385-91. PubMed ID: 24449317
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of pivotal trials and FDA review of innovative devices.
Rising JP; Moscovitch B
PLoS One; 2015; 10(2):e0117235. PubMed ID: 25651420
[TBL] [Abstract][Full Text] [Related]
10. Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA.
Swanson MJ; Johnston JL; Ross JS
Trials; 2021 Nov; 22(1):817. PubMed ID: 34789308
[TBL] [Abstract][Full Text] [Related]
11. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports.
Chang L; Dhruva SS; Chu J; Bero LA; Redberg RF
BMJ; 2015 Jun; 350():h2613. PubMed ID: 26063311
[TBL] [Abstract][Full Text] [Related]
12. Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015.
Gopal AD; Rathi VK; Teng CC; Del Priore L; Ross JS
Ophthalmology; 2017 Aug; 124(8):1237-1246. PubMed ID: 28501378
[TBL] [Abstract][Full Text] [Related]
13. Pivotal trials of orthopedic surgical devices in the United States: predominance of two-arm non-inferiority designs.
Golish SR
Trials; 2017 Jul; 18(1):348. PubMed ID: 28738891
[TBL] [Abstract][Full Text] [Related]
14. Radiological Medical Device Innovation: Approvals via the Premarket Approval Pathway From 2000 to 2015.
Ghobadi CW; Hayman EL; Finkle JH; Walter JR; Xu S
J Am Coll Radiol; 2017 Jan; 14(1):24-33. PubMed ID: 28061962
[TBL] [Abstract][Full Text] [Related]
15. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices.
Dhruva SS; Bero LA; Redberg RF
JAMA; 2009 Dec; 302(24):2679-85. PubMed ID: 20040556
[TBL] [Abstract][Full Text] [Related]
16. Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications.
Lee SJ; Cho L; Klang E; Wall J; Rensi S; Glicksberg BS
JAMA Netw Open; 2021 Jun; 4(6):e2112562. PubMed ID: 34156454
[TBL] [Abstract][Full Text] [Related]
17. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval.
Psotka MA; von Maltzahn R; Anatchkova M; Agodoa I; Chau D; Malik FI; Patrick DL; Spertus JA; Wiklund I; Teerlink JR
JACC Heart Fail; 2016 Oct; 4(10):791-804. PubMed ID: 27395351
[TBL] [Abstract][Full Text] [Related]
19. An overview of Food and Drug Administration regulation of drugs, biologics, and devices to be used for management of periodontal diseases.
Tylenda CA; Weintraub M
Ann Periodontol; 1997 Mar; 2(1):11-7. PubMed ID: 9151539
[TBL] [Abstract][Full Text] [Related]
20. Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014.
Rathi VK; Wang B; Ross JS; Downing NS; Kesselheim AS; Gray ST
Otolaryngol Head Neck Surg; 2017 Feb; 156(2):285-288. PubMed ID: 28093943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]